Billionaire Ken Griffin Boosted His Stake in This Dividend King by 146%. Here's Why It's a Dream Stock for Risk-Averse Investors.

Ken Griffin increased his stake in Johnson & Johnson by 146% in Q1 2026, bringing his total holdings to nearly 2 million shares. The article highlights J&J as an ideal stock for risk-averse investors due to its diversified portfolio of 28+ billion-dollar products, strong revenue growth in pharmaceuticals and medtech following the Kenvue spinoff, and its status as a Dividend King with 50+ consecutive years of dividend increases and a 2% yield.

07/12/2026, 5:10 PM • The Motley Fool

History Says Doing This 1 Thing Will Score You an Investing Win -- Even After a Market Crash.

Despite recent market gains driven by AI stocks, valuations are at historically expensive levels similar to the dot-com bubble. The article recommends a simple strategy: invest in quality stocks and hold them long-term. History shows the S&P 500 has always recovered after crashes, making buy-and-hold the key to investing success.

07/11/2026, 4:02 AM • The Motley Fool

Explosive Growth in AI for Orthopedic Surgery Market: $0.87 Billion by 2030 at 27.2% CAGR

The AI in orthopedic surgery market is experiencing remarkable growth with a projected CAGR of 27.2% through 2030. Key drivers include rising musculoskeletal disorders, AI-assisted surgical planning, robotic surgical systems integration, and enhanced implant placement precision. North America leads the market, while Asia-Pacific and Europe show growing segments despite tariff-related challenges.

07/10/2026, 10:56 AM • GlobeNewswire

Vanguard Health Care vs. VanEck Pharmaceutical: How Do These ETFs Stack Up?

Vanguard Health Care ETF (VHT) offers broad diversification across 429 healthcare holdings with a low 0.09% expense ratio, while VanEck Pharmaceutical ETF (PPH) provides concentrated exposure to 26 drugmakers with higher returns but greater risk. VHT is more cost-effective and diversified, while PPH has delivered superior 5-year returns and higher dividend yield despite concentration risk and a higher 0.36% expense ratio.

07/09/2026, 8:15 AM • The Motley Fool

Invesco Pharmaceuticals ETF or First Trust Biotech Fund: Which Drug Maker-Focused Fund Should You Buy in 2026?

The article compares two healthcare-focused ETFs: Invesco Pharmaceuticals ETF (PJP) and First Trust NYSE Arca Biotechnology Index Fund (FBT). PJP focuses on established pharmaceutical companies with lower volatility and dividend income, while FBT targets high-growth biotech stocks with greater exposure to small and mid-cap companies. Despite FBT's stronger 10-year performance, PJP is recommended as the better buy due to its superior 5-year returns, lower volatility, dividend yield, and more stable risk profile.

07/08/2026, 6:04 PM • The Motley Fool

This 4.5%-Yielding Dividend Stock Is Beating the S&P 500 and the Nasdaq. 3 Reasons That Can Continue in the Second Half of 2026

Kimberly-Clark is outperforming the S&P 500 and Nasdaq in 2026 with a 4.5% dividend yield and 54 consecutive years of dividend increases. The company trades at a discount valuation (15.2x 2026 earnings vs. 21.9x historical median) and is acquiring Kenvue to diversify revenue streams and unlock $2.1 billion in annual synergies. However, risks include execution challenges from the acquisition and potential dividend sustainability concerns.

07/08/2026, 8:05 AM • The Motley Fool

BBH vs. XPH: Which Healthcare ETF Is Better for Beginners?

The article compares two healthcare ETFs: VanEck Biotech ETF (BBH) with 25 concentrated holdings and State Street SPDR S&P Pharmaceuticals ETF (XPH) with 65 diversified holdings. Both charge identical 0.35% expense ratios and offer 0.50% dividend yields, but XPH delivered significantly higher 1-year returns (64.30% vs 33.30%) and lower volatility, making it potentially more suitable for beginners seeking diversification.

07/08/2026, 7:28 AM • The Motley Fool

2 Dirt Cheap Dividend Stocks to Buy With $1,000 Right Now

Pfizer and Bristol Myers Squibb are presented as attractively valued dividend stocks despite recent challenges. Both pharmaceutical companies face patent cliffs but have strong pipelines with promising candidates in oncology, weight loss, and anticoagulants. With forward yields of 7.1% and 4.3% respectively, and trading at discounted valuations (8.2x and 9x forward earnings), they are recommended as potential buys for dividend investors with $1,000 to deploy.

07/07/2026, 6:30 PM • The Motley Fool

3 Stocks to Buy and Hold: The Long-Term Play for Your Portfolio

The article recommends three healthcare stocks for long-term buy-and-hold portfolios: Johnson & Johnson, Abbott Laboratories, and UnitedHealth Group. All three are praised for their stable dividends, strong cash flows, economic moats, and ability to weather economic downturns. Johnson & Johnson and Abbott are Dividend Kings with 64 and 54 consecutive years of dividend increases respectively, while UnitedHealth Group benefits from its dual-engine model combining insurance and healthcare delivery.

07/06/2026, 8:30 AM • The Motley Fool

3 Dividend ETF Picks That Could Build Serious Long-Term Wealth

The article examines three dividend-focused ETFs as wealth-building alternatives to growth stocks. SCHD offers higher yields through value-oriented dividend stocks, VIG combines growth potential with rising dividends, and DGRO provides a balanced hybrid approach. All three can build serious long-term wealth through dividend reinvestment if held patiently.

07/05/2026, 5:20 PM • The Motley Fool

Fidelity Health Care vs. State Street Biotech: Which ETF Fits Your Portfolio Best?

The Fidelity MSCI Health Care Index ETF (FHLC) offers broad healthcare sector exposure with lower costs (0.08% expense ratio), higher dividend yield (1.3%), and lower volatility, making it suitable for conservative investors. The State Street SPDR S&P Biotech ETF (XBI) focuses on biotechnology with higher growth potential (89.3% 1-year return) but carries significantly higher risk (54% maximum drawdown) and costs (0.35% expense ratio), appealing to aggressive investors.

07/05/2026, 9:15 AM • The Motley Fool

Biogen Is Paying $1 Billion for a Company That Won't Say What It Makes. Here's Why That's Actually Good News for BIIB Investors.

Biogen announced a $1 billion acquisition of RayThera, a company with anti-inflammatory assets targeting immune-mediated conditions. This strategic move strengthens Biogen's immunology portfolio following its earlier acquisition of Apellis Pharmaceuticals. The company is successfully transitioning from its declining MS drug business to growth areas like Alzheimer's and rare diseases, with early signs of business stabilization and revenue growth.

07/04/2026, 4:02 AM • The Motley Fool

Johnson & Johnson Is Walking Away From a $100 Billion Obesity Market. Could That Actually Make It the Better Long-Term Buy Than Eli Lilly?

Johnson & Johnson is deliberately avoiding the competitive GLP-1 weight-loss drug market, instead focusing on oncology and its medical device business where it has established strengths. This diversified strategy, combined with a lower valuation (P/E of 29x vs. Eli Lilly's 40x+) and higher dividend yield (2.1% vs. 0.6%), may make J&J a more attractive long-term investment despite missing out on the hot obesity drug trend.

07/03/2026, 9:15 PM • The Motley Fool

[Latest] Global Gauze Bandage Rolls Market Size/Share Worth USD 3.19 Billion by 2035 at a 4.97% CAGR: Healthcare Foresights (Analysis, Outlook, Leaders, Report, Trends, Forecast, Segmentation, Growth Rate, Value, SWOT Analysis)

The global gauze bandage rolls market is valued at USD 1.96 billion in 2025 and is projected to reach USD 3.19 billion by 2035, growing at a CAGR of 4.97%. Growth is driven by rising surgical procedures, aging populations, chronic wound management, and technological advancements in antimicrobial and bioactive gauze products. Key market segments include cotton gauze (largest share), surgical wounds (dominant application), and hospitals (primary end-user), with Asia Pacific expected to show the fastest growth.

07/03/2026, 12:30 AM • GlobeNewswire

UnitedHealth is Near its 52-Week High. Wall Street Is Starting to Notice This Blue Chip Stock -- and So Should You.

UnitedHealth Group (UNH) has surged 25% this year and is trading near its 52-week high. The healthcare giant offers revenue growth, a solid 2.3% dividend yield with 17 consecutive years of increases, and resilience against economic downturns. The company is deploying a $1.5 billion AI initiative to reduce administrative costs and improve margins, while managing rising medical costs through responsive pricing strategies. Despite valuation concerns and industry-wide medical cost pressures, UnitedHealth's diversified business model and strong cash flow position it as an attractive investment for income and total-return focused investors.

06/26/2026, 3:30 PM • The Motley Fool